Evidence map›Paper›PMID 40635093›Full record

ReviewEuropean journal of medical research2025

The role of the gut microbiota and its metabolites: a new predictor in diabetes and its complications.

Kaile Wu, Yang Xiao, Tianjun Zhang, Yunlong Bai, Meiling Yan

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kaile WuGuangdong Metabolic Diseases Research Center of Integrated Chinese and Western MedicineKey Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of ChinaGuangdong Key Laboratory of Metabolic Disease Prevention and Treatment of Traditional Chinese MedicineInstitute of Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, Guangdong Province, China.
Yang XiaoGuangdong Metabolic Diseases Research Center of Integrated Chinese and Western MedicineKey Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of ChinaGuangdong Key Laboratory of Metabolic Disease Prevention and Treatment of Traditional Chinese MedicineInstitute of Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, Guangdong Province, China.
Tianjun ZhangHuadu District People's Hospital of Guangzhou, Guangzhou, Guangdong Province, China.
Yunlong BaiGuangdong Metabolic Diseases Research Center of Integrated Chinese and Western MedicineKey Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of ChinaGuangdong Key Laboratory of Metabolic Disease Prevention and Treatment of Traditional Chinese MedicineInstitute of Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, Guangdong Province, China. ylbai@gzucm.edu.cn.
Meiling YanGuangdong Metabolic Diseases Research Center of Integrated Chinese and Western MedicineKey Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of ChinaGuangdong Key Laboratory of Metabolic Disease Prevention and Treatment of Traditional Chinese MedicineInstitute of Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, Guangdong Province, China. yanmeiling0122@gdpu.edu.cn.ORCID http://orcid.org/0000-0001-7652-129X

Funding

Guangzhou Science and Technology Bureau SL2024A04J00652 to M. YYanMeiling 82304481
6 · The paper itself

Abstract

Type 2 diabetes (T2D) is easy to trigger many organ or system lesions, which can lead to various metabolic diseases, such as diabetic kidney disease (DKD), diabetic liver disease, diabetic cardiovascular disease, diabetic foot, etc. Due to the easy availability of stool and blood samples from patients, the study of gut microbes and their metabolites are progressing rapidly. The relationship between pathophysiological alterations of metabolic disorders and gut microbiota composition provides new approaches to precisely identify disease dynamics and refine disease treatment strategies. The aim of this review is to investigate the association between T2D with its complications and gut microbiota. Gut microbial metabolites are a new class of signaling molecules, and the mechanisms and pathways of their signal transduction have also been extensively studied. As a result, we will focus on the characteristics of gut microbiota and its metabolites in metabolic diseases as well as the relationship between gut barrier theory and the circulation of gut microbiota-derived metabolites in vivo. In addition, we elucidate the potential applicability of these characterizations and molecular mechanisms in clinical and pharmacological environment, analyzing their feasibility as predictive molecules for health management and clinically accurate predictions in daily life.

Indexed as

Diabetes ComplicationsDiabetes Mellitus, Type 2Gastrointestinal MicrobiomeHumansGut barrierGut microbiotaGut microbiota metabolitesHealth managementMetabolic disorderT2D

Identifiers

PMID40635093
PMCPMC12239269

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.